Insulin preparation for non-parenteral administration

• US 5,053,389 A
• Filed: 12/14/1987
• Issued: 10/01/1991
• Est. Priority Date: 04/18/1986
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Balschmidt, Per, Hansen, Finn B., Johansen, Bente R.
• Primary Examiner(s): NOT, DEFINED
• Application Number:
  US07/132,969
• Time in Patent Office: 1,387 Days
• Field of Search: 514/3, 514/4, 514/866, 530/303, 530/304, 530/305
• US Class Current: 514/6.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: C07K 14/62 Insulins

Abstract

Insulin preparations for non-parenteral administration and containing one or more insulins or insuling derivatives, which in solution in the physiological pH range predominantly are present as monomers, usual additives and possibly a conventional insulin and possibly one or more adsorption promoting substances provide a fast absorption of the insulin activity administered.

Claims

1. A method for treating diabetes in a warm-blooded animal by non-parenterally administering to said warm blooded animal an insulin preparation comprising des[(B26-30)-pentapeptide] insulin-B25-amide, an absorption promoting substance, a physiologically acceptable additive and, optionally, a conventional insulin.

2. The method according to claim 1, wherein said insulin preparation is administered nasally.

3. Insulin preparation for non-parenteral administration comprising des[(B26-30)-pentapeptide] insulin-B-25-amide, an absorption promoting substance, a physiologically acceptable additive and, optionally, a conventional insulin.